S-2
S-2 Symposium: Corneal Collagen Crosslinking: Where Are We Now and What Does the Future Hold?

Saturday, April 26, 2014: 1:00 PM-2:30 PM
Room 204AB (Boston Convention and Exhibition Center)

Narrative Responses:

Abstract
Sponsored by the ASCRS FDA Committee

 

Moderator:  Michael W. Belin, MD, Chair

ASCRS FDA Committee

 

Panelists: Wiley Chambers

Deputy Director of the Division of Transplant and Ophthalmology Products, Center for Drug Evaluation and Research, Food and Drug Administration

 

Sheraz M. Daya, MD, FACS

Chairman and Medical Director, Centre for Sight

 

Doyle Stulting, MD, PhD

Director, Stulting Research Center, Professor of Ophthalmology, Emory University

 

William J. Link, PhD

Managing Director, Versant Ventures

 

Simon J. Dean, FRANZCO, FBCLA

Associate, Eye Institute Vision Correction Specialists

The 2014 FDA Symposium will focus on corneal collagen crosslinking.  The session will feature remarks from Wiley Chambers, Deputy Director of the Division of Transplant and Ophthalmology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, who will address why the approval process is ongoing and the current status of corneal crosslinking in the United States.

Panelists will discuss the current available data on corneal collagen crosslinking.  The discussion will also provide a summary of regulatory constraints on approval of this procedure and what it would take to get corneal crosslinking approved.

Moderator:
Michael W. Belin, MD
Panelists:
Sheraz M. Daya, MD, FACS , Doyle Stulting, MD, PhD , William J. Link, PhD and Simon John Dean, FRANZCO, FBCLA
See more of: ASCRS Symposium